We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 0.06% | 1,819.00 | 1,819.00 | 1,821.00 | 1,832.00 | 1,813.00 | 1,825.00 | 396,909 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.96 | 4.02B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 1352R
Hikma Pharmaceuticals Plc
06 December 2016
Hikma Pharmaceuticals PLC
Voting Rights and Capital
LONDON, 6 December 2016, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 239,954,532 ordinary shares with voting rights. There are nil shares held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and Transparency Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC Peter Speirs Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAPAKEEDKFFF
(END) Dow Jones Newswires
December 06, 2016 13:04 ET (18:04 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
